Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its position in shares of Repare Therapeutics Inc. (NASDAQ:RPTX) by 10.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 249,215 shares of the company’s stock after selling 27,953 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Repare Therapeutics were worth $857,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in RPTX. Vontobel Holding Ltd. increased its holdings in Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after buying an additional 4,000 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Repare Therapeutics by 21.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after acquiring an additional 8,809 shares during the period. Blue Owl Capital Holdings LP increased its stake in shares of Repare Therapeutics by 8.0% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock valued at $11,129,000 after purchasing an additional 250,000 shares in the last quarter. Squarepoint Ops LLC raised its holdings in Repare Therapeutics by 428.4% in the 2nd quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock worth $472,000 after purchasing an additional 115,916 shares during the period. Finally, Marshall Wace LLP acquired a new position in Repare Therapeutics in the 2nd quarter worth about $273,000. 85.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Repare Therapeutics in a report on Friday, November 8th. Lifesci Capital raised shares of Repare Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th.

Repare Therapeutics Stock Down 1.0 %

RPTX opened at $2.88 on Wednesday. The company has a market cap of $122.43 million, a PE ratio of -1.44 and a beta of 0.72. Repare Therapeutics Inc. has a twelve month low of $2.71 and a twelve month high of $8.49. The company has a 50-day moving average price of $3.41 and a 200 day moving average price of $3.40.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.